Rationale for intermittent renal replacement therapy (IRRT) in acute renal failure (ARF)

  • Bernard Canaud
  • Hélène Leray-Moragues
  • Laurie Garred
  • Martine Leblanc
  • Charles Mion


Choosing a treatment modality for an acute renal failure (ARF) patient is always a challenging problem for the physician [1]. The principal objective is to provide an adequate or even an optimal treatment without adversely affecting patient outcome, while not further compromising renal functional recovery [2, 3]. One has to match the dialysis dose to the particular patient needs while providing adequate protein and caloric intake. One must also try to prevent further hemodynamic compromise and consequently additional renal injury [2, 3, 4].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kjellstrand CM, Teehan BR Acute renal failure. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF (eds). Replacement of renal function by dialysis. Fourth edition. Dordrecht: Kluwer Academic Publishers, 1996: 821–62.CrossRefGoogle Scholar
  2. 2.
    Conger JD. Does hemodialysis delay recovery from acute renal failure? Semin Dial 1990; 3: 146–8.CrossRefGoogle Scholar
  3. 3.
    Manns M, Sigler MH, Teehan BR Advantage of continuous veno-venous hemodialysis in acute renal failure. J Am Soc Nephrol 1995; 6: 470.Google Scholar
  4. 4.
    Firth JD. Renal replacement therapy in the intensive care unit. Q J Med 1993; 86: 75–7.PubMedGoogle Scholar
  5. 5.
    Canaud B, Mion C. Extracorporeal treatment of acute renal failure: methods, indications, quantified and personalized therapeutic approach. Adv Nephrol 1995; 24: 271–81.Google Scholar
  6. 6.
    Maher ER, Robinson KN, Scoble JE, et al. Prognosis of critically-ill patients with acute renal failure: APACHE II score and other predictive factors. Q J Med 1989; 72: 857–66.PubMedGoogle Scholar
  7. 7.
    Mehta RL. Therapeutic alternatives to renal replacement for critically ill patients in acute renal failure. Semin Nephrol 1994; 14: 64–82.PubMedGoogle Scholar
  8. 8.
    Ronco C. Continuous renal replacement therapies in the treatment of acute renal failure in intensive care patients: theoretical aspects and techniques. Nephrol Dial Transplant 1994; 9: S191–200.Google Scholar
  9. 9.
    Ronco C. Continuous renal replacement therapies in the treatment of acute renal failure in intensive care patients: clinical indications and prescription. Nephrol Dial Transplant 1994; 9: S201–9.Google Scholar
  10. 10.
    Schetz M, Ferdinande P, van der Berghe G, Verwaest C, Lauwers P. Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med 1995; 21: 169–76.PubMedCrossRefGoogle Scholar
  11. 11.
    Henrich WL. Arteriovenous or venovenous continuous therapies are not superior to standard hemodialysis in all patients with acute renal failure. Semin Dial 1993; 6: 174–6.CrossRefGoogle Scholar
  12. 12.
    Jacobs SM, Frey FJ, Uehlinger DE. Does CRRT favourably influence the outcome of the patients? Nephrol Dial Transplant 1996; 11: 1250–5.CrossRefGoogle Scholar
  13. 13.
    Clark WR, Mueller BA, Alaka KJ, Macias WL. A comparison of metabolic control by continuous and intermittent therapies in acute renal failure. J Am Soc Nephrol 1994; 4: 1413–20.PubMedGoogle Scholar
  14. 14.
    Kleinknecht D, Jungers P, Chanard J, Barbanel C, Ganeval D. Uremic and nonuremic complications in acute renal failure: evaluation of early and frequent dialysis on prognosis. Kidney Int 1972; 1: 190–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Chima CS, Meyer L, Hummell C, Bosworth C, Heyka R, Paganini ER Protein catabolic rate in patients with acute renal on continuous arteriovenous hemofiltration and total parenteral nutrition. J Am Soc Nephrol 1993; 3: 1516–21.PubMedGoogle Scholar
  16. 16.
    Macias WL, Clark WR. Azotemia control by extracorporeal therapy in patients with acute renal failure. New Horizons 1995; 3: 688–98.PubMedGoogle Scholar
  17. 17.
    Maeda K, Kawaguchi S, Kobayashi S, Niwa T, Kobayashi K, Saito A, Lyoda S, Ohta K. Cell-wash dialysis. Trans Am Soc Artif Intern Organs 1980; 26: 213–8.PubMedGoogle Scholar
  18. 18.
    Lowell JA, Schifferdecker C, Driscoll DF, Benotti PN, Bistrian BR. Postoperative fluid overload: not a benign problem. Crit Care Med 1990; 18: 728–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Bergamo Collaborative Dialysis Study Group. Acute intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophan. Kidney Int 1991; 40: 714–9.CrossRefGoogle Scholar
  20. 20.
    Kierdorf HP. The nutritional management of acute renal failure in the intensive care unit. New Horizons 1995; 3: 699–707.PubMedGoogle Scholar
  21. 21.
    Sponsel H, Conger JD. Is parenteral nutrition therapy of value in acute renal failure? Am J Kidney Dis 1995; 25: 96–102.PubMedCrossRefGoogle Scholar
  22. 22.
    Davenport A, Roberts NB. Amino acid losses during continuous high flux hemofiltration in the critically ill patient. Crit Care Med 1989; 17: 1010–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Mokrzycki MH, Kaplan AA. Hemofiltrate protein losses in continuous renal replacement therapies. J Am Soc Nephrol 1995; 6: 584.Google Scholar
  24. 24.
    Goldstein DJ, Strom JA. Intradialytic parenteral nutrition: evolution and current concepts. J Ren Nutr 1991; 1: 9–17.Google Scholar
  25. 25.
    Schwab SJ, Onorato JJ, Sharar LR. Hemodialysis without anticoagulation. One year prospective trial in hospitalized patients at risk for bleeding. Am J Med 1987; 83: 405–10.PubMedCrossRefGoogle Scholar
  26. 26.
    Spurney RF, Fulkerson WJ, Schwab SJ. Acute renal failure in critically ill patients: prognosis for recovery of kidney function after prolonged dialysis support. Crit Care Med 1991; 19: 8–11.PubMedCrossRefGoogle Scholar
  27. 27.
    Cameron JS. Acute renal failure thirty years on. Q J Med 1990; 74: 1–2.PubMedGoogle Scholar
  28. 28.
    Biesenback G, Zazgornick J, Kaiser W, Grafinger P, Stuby U, Necek S. Improvement in prognosis of patients with acute renal failure over a period of 15 years: an analysis of 710 cases in a dialysis center. Am J Nephrol 1992; 12: 319–25.CrossRefGoogle Scholar
  29. 29.
    Turney JH. Acute renal failure: some progress? N Engl J Med 1994; 331: 1372–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Cosentino F, Chaff C, Piedmonte M. Risk factors influencing survival in ICU acute renal failure. Nephrol Dial Transplant 1994; 9: S179–82.Google Scholar
  31. 31.
    Schiffl H, Lang SM, Strasser T, Haider MC, Held E. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994; 344: 570–2.PubMedCrossRefGoogle Scholar
  32. 32.
    Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994; 331: 1338–42.PubMedCrossRefGoogle Scholar
  33. 33.
    Locatelli F. Influence of membranes on morbidity. Nephrol Dial Transplant 1996; 11: 116–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Hakim RM, Himmelfarb J. Biocompatibility: principles. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF (eds). Replacement of renal function by dialysis. Fourth edition. Dordrecht: Kluwer Academic Publishers, 1996: 178–87.CrossRefGoogle Scholar
  35. 35.
    Kränzlin B, Reuss A, Ryan CJ, Gretz N, Strauch M. Does the use of dialyzers based on a cuprophane membrane delay the recovery from acute renal failure. Eur J Clin Invest 1994; 24: A26.Google Scholar
  36. 36.
    Mujais S, Ivanovich R Haemodialysis membranes (Letter). Lancet 1994; 344: 1362.PubMedCrossRefGoogle Scholar
  37. 37.
    Kaplan A.A. Haemodialysis membranes (Letter). Lancet 1994; 344: 1363.PubMedCrossRefGoogle Scholar
  38. 38.
    Boulton-Jones M. Dialysis membranes: clinical effects. Lancet 1994; 344: 559.PubMedCrossRefGoogle Scholar
  39. 39.
    Cheung AK. Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990; 1: 150–61.PubMedGoogle Scholar
  40. 40.
    Hakim RM, Himmelfarb J. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44: 484–94.PubMedCrossRefGoogle Scholar
  41. 41.
    Hakim RM. Clinical sequelae of complement activation in hemodialysis. Clin Nephrol 1986; 26: S9 - S12.PubMedGoogle Scholar
  42. 42.
    Lang S, Küchle C, Fricke H, Schiffl H. Biocompatible intermittent hemodialysis. New Horizons 1995; 3: 6807.Google Scholar
  43. 43.
    Oba T, Tsuji K, Nakamura A, Shintani H, Mizumachi S, Kikuchi H, Kaniwa MA, Kojima S, Kanohta K, Kawasaki Y, Furuya T, Matsumoto K, Tobe M. Migration of acetylated hemicellulose from capillary hemodiayzer to blood, causing scleritis and/or iritis. Artif Organs 1984; 8: 429–35.PubMedCrossRefGoogle Scholar
  44. 44.
    Bommer J, Ritz E, Andrassy K. Side effects due to materials used in hemodialysis equipment. Adv Nephrol 1984; 13: 409–38.Google Scholar
  45. 45.
    Stiekema JCJ. Heparin and its biocompatibility. Clin Nephrol 1986; 26: S3–8.PubMedGoogle Scholar
  46. 46.
    Tetta C, Segoloni G, Mariano F, Montrucchio G, Turello E, Camussi G. Leukocyte-derived mediators and biocompatibility. Nephrol Dial Transplant 1991; S2430.Google Scholar
  47. 47.
    David S, Tetta C, Camussi G, et al. Adherence of human monocytes to haemodialysis membranes. Nephrol Dial Transplant 1993; 8: 1223–7.PubMedGoogle Scholar
  48. 48.
    Schulman G, Fogo A, Gung A, Badr K, Hakim R. Complement activation retards resolution of acute ischemic renal failure in the rat. Kidney Int 1991; 40: 1069–74.PubMedCrossRefGoogle Scholar
  49. 49.
    Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59: 879–88.PubMedCrossRefGoogle Scholar
  50. 50.
    Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Eng J Med 1977; 296: 769–812.CrossRefGoogle Scholar
  51. 51.
    Spagnuolo BJ, Bass SH, Smith MC, Danviriyasup K, Dunn MJ. Neutrophil adhesiveness during prostacyclin and heparin hemodialysis. Blood 1982; 60: 924–9.PubMedGoogle Scholar
  52. 52.
    Hörl WH, Steinhauer HB, Schollmeyer P. Plasma levels of granulocytes elastase during hemodialysis: effects of different dialyzer membranes. Kidney Int 1985; 28: 791–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Heidland A, Hörl WH, Heller N, Heine H, Siegfried N, Heidbreder E. Proteolytic enzymes and catabolism: enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis. Kidney Int 1983; 24: S27–36.CrossRefGoogle Scholar
  54. 54.
    Kuwahara T, Markert M, Wauters JR Neutrophil oxygen radical production by dialysis membranes. Nephrol Dial Transplant 1988; 3: 661–5.PubMedGoogle Scholar
  55. 55.
    Cristol JP, Canaud B, Damon M, Chavis C, Arnoux B, Mion C. Platelet-activating factor production during hemodialysis: effect of BN 52021. Prostaglandins Leukotrienes Essential Fatty Acids 1992; 45: 37–42.CrossRefGoogle Scholar
  56. 56.
    Knudsen F, Nielsen AH, Pedersen JO, Grunnet, Jersild C. Adult respiratory distress-like syndrome during hemodialysis: relationship between activation of complement, leukopenia, and release of granulocyte elastase. Int J Artif Organs 1985; 8: 187–94.PubMedGoogle Scholar
  57. 57.
    Dinarello CA. The biology of interleukin-1 and its relevance to hemodialysis. Blood Purif 1983: 1: 197–203.CrossRefGoogle Scholar
  58. 58.
    Haeffner-Cavaillon N, Jahns G, Poignet JL, Kazatchkine D. Induction of interleukin-1 during hemodialysis. Kidney Int 1993; 43: S139–43.Google Scholar
  59. 59.
    Haeffner-Cavaillon N, Fischer E, Bade F, et al. Complement activation and induction of interleukin-1 production during hemodialysis. Contrib Nephrol 1988; 62: 86–98.PubMedGoogle Scholar
  60. 60.
    Chatenoud L, Jungers P, Descamps-Latcha B. Immunological considerations of the uremic and dialyzed patient. Kidney Int 1994; 45: S92–6.Google Scholar
  61. 61.
    Arese M, Cristol JP, Bosc JY, et al. Removal of constitutive and inducible nitric oxide synthase-active compounds in a modified hemodiafiltration with on-line production of substitution fluid: the contribution of convection and diffusion. Intern J Artif Organs 1996; 19: 25–32.Google Scholar
  62. 62.
    Gutierrez A, Alvestrand A, Bergström J, Beving H, Lantz B, Henderson LD. Biocompatibility of hemodialysis membranes: a study in healthy subjects. Blood Purif 1994; 12: 95–105.PubMedCrossRefGoogle Scholar
  63. 63.
    Humes HD, Liu S. Cellular and molecular basis of renal repair in acute renals failure. J Lab Clin Med 1994; 124: 749–54.PubMedGoogle Scholar
  64. 64.
    Haubitz M, Shulze M, Koch KM. Increase of C-reactive protein serum values following haemodialysis. Nephrol Dial Transplant 1990; 5: 500–3.PubMedCrossRefGoogle Scholar
  65. 65.
    Bellomo R, Tipping P, Boyce N. Tumor necrosis factor clearances during veno-venous hemodiafiltration in the critically ill. Trans Am Soc Artif Organs 1992; 37: M323–4.Google Scholar
  66. 66.
    Barzilay E, Kessler E, Berlot G. Use of extracorporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients. Crit Care Med 1989; 17: 634–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Deppisch R, Ritz E, Hänsch M, Schöls M, Rauterberg E.W. Bioincompatibility-perspectives in 1993. Kidney Int 1994; 44: S77–84.Google Scholar
  68. 68.
    Mujais S.K, Ivanovich P, Vidovich MI. Dialysis in acute renal failure: which membrane? Artif Organs 1994; 18: 470–2.PubMedCrossRefGoogle Scholar
  69. 69.
    Sweet SJ, McCarthy S, Steingart R, Callahan T. Hemolytic reactions mechanically induced by kinked hemodialysis lines. Am J Kidney Dis 1996; 27: 262–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Gault MH, Duffett S, Purchase L, Murphy J. Hemodialysis intravascular hemolysis and kinked blood lines. Nephron 1992; 62: 267–71.PubMedCrossRefGoogle Scholar
  71. 71.
    Hudson S, Taylor JE, Stewart WK. Undetect excessive ultrafiltration and serious haemolysis during maintenance haemodialysis. Nephrol Dial Transplant 1993; 8: 477–9.PubMedGoogle Scholar
  72. 72.
    Kerkay J, Nakamoto S. Plasticizers and the uremic patients. Int J Artif Organs 1979; 2: 107–12.PubMedGoogle Scholar
  73. 73.
    Flaminio LM, de Angelis L, Ferazza M, Mannovich M, Galli G, Galli CL. Leechability of a new plasticizer tri(2-ethyl-hexi) trimellitate from haemodialysis tubing. Int J Artif Organs 1988; 11: 435–9.PubMedGoogle Scholar
  74. 74.
    Bommer J, Gemsa D, Waldherr R, Kessler J, Ritz E. Plastic filing from dialysis tubing induces prostanoid release from macrophages. Kidney Int 1984; 26: 331–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Barron D, Harbottle S, Hoenich NA, Morley AR, Appleton D, McCabe JF. Particle spallation induced by blood pumps in hemodialysis tubing sets. Artif Organs 1986; 10: 226–35.PubMedCrossRefGoogle Scholar
  76. 76.
    Martin RK, Jurschak J. Nursing management of continuous renal replacement therapy. Semin Dial 1996; 9: 192–9.CrossRefGoogle Scholar
  77. 77.
    Moreno L, Heyka R, Paganini EP. Continuous renal replacement therapies: cost considerations and reimbursement. Semin Dial 1996; 9: 209–14.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • Bernard Canaud
  • Hélène Leray-Moragues
  • Laurie Garred
  • Martine Leblanc
  • Charles Mion

There are no affiliations available

Personalised recommendations